SEELOS THERAPEUTICS INC (SEEL)

US81577F2083 - Common Stock

0.255  -0.02 (-7.31%)

Fundamental Rating

1

Overall SEEL gets a fundamental rating of 1 out of 10. We evaluated SEEL against 197 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of SEEL have multiple concerns. SEEL does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

SEEL had negative earnings in the past year.
SEEL had a negative operating cash flow in the past year.
SEEL had negative earnings in each of the past 5 years.
In the past 5 years SEEL always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of SEEL (-699.21%) is worse than 97.95% of its industry peers.
Industry RankSector Rank
ROA -699.21%
ROE N/A
ROIC N/A
ROA(3y)-367.17%
ROA(5y)-334.5%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

SEEL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for SEEL has been reduced compared to 1 year ago.
Compared to 5 years ago, SEEL has more shares outstanding
SEEL has a worse debt/assets ratio than last year.

2.2 Solvency

SEEL has an Altman-Z score of -96.89. This is a bad value and indicates that SEEL is not financially healthy and even has some risk of bankruptcy.
SEEL's Altman-Z score of -96.89 is on the low side compared to the rest of the industry. SEEL is outperformed by 95.90% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -96.89
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 0.14 indicates that SEEL may have some problems paying its short term obligations.
SEEL's Current ratio of 0.14 is on the low side compared to the rest of the industry. SEEL is outperformed by 98.97% of its industry peers.
SEEL has a Quick Ratio of 0.14. This is a bad value and indicates that SEEL is not financially healthy enough and could expect problems in meeting its short term obligations.
SEEL's Quick ratio of 0.14 is on the low side compared to the rest of the industry. SEEL is outperformed by 98.97% of its industry peers.
Industry RankSector Rank
Current Ratio 0.14
Quick Ratio 0.14

More info and screens

3

3. Growth

3.1 Past

The earnings per share for SEEL have decreased strongly by -34.72% in the last year.
EPS 1Y (TTM)-34.72%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q84.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

SEEL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.63% yearly.
The Revenue is expected to grow by 195.91% on average over the next years. This is a very strong growth
EPS Next Y90.84%
EPS Next 2Y40.63%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-81.25%
Revenue Next 2Y321.31%
Revenue Next 3Y402.41%
Revenue Next 5Y195.91%

3.3 Evolution

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SEEL. In the last year negative earnings were reported.
Also next year SEEL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

SEEL's earnings are expected to grow with 40.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.63%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SEEL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SEELOS THERAPEUTICS INC

NASDAQ:SEEL (5/14/2024, 11:27:25 AM)

0.255

-0.02 (-7.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.24M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -699.21%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.14
Quick Ratio 0.14
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-34.72%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y90.84%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y